Elevar Therapeutics files EMA application for lirafugratinib in CCA

Elevar Therapeutics has submitted a marketing authorisation application (MAA) to the European Medicines Agency for lirafugratinib, an oral, irreversible FGFR2-selective inhibitor, as a second-line treatment for patients with advanced or metastatic cholangiocarcinoma (CCA) harbouring FGFR2 fusions or rearrangements. The submission follows a New Drug Application filed with the US Food and Drug Administration in January 2026, which was granted Priority Review and carries a PDUFA target action date of 25 September 2026.

The EMA filing is supported by the Phase 1/2 ReFocus study, in which lirafugratinib achieved an objective response rate of 46.5% by independent review committee in FGFR2 fusion-positive CCA patients who had received at least one prior line of systemic therapy. Median duration of response was 11.8 months, median progression-free survival was 11.3 months, and median overall survival reached 22.8 months. These figures represent a clinically meaningful dataset for a rare and difficult-to-treat malignancy in which second-line options remain limited.

Differentiation from pan-FGFR inhibitors

Lirafugratinib's key mechanistic claim rests on its selectivity. Existing approved FGFR inhibitors, such as pemigatinib and futibatinib, broadly target multiple members of the FGFR family, including FGFR1, FGFR3, and FGFR4. Elevar argues that targeting FGFR2 alone reduces off-target toxicity; in ReFocus, rates of hyperphosphataemia and diarrhoea, the adverse events most commonly associated with pan-FGFR inhibition, were 20.7% and 21.6% respectively. Whether those tolerability figures translate into a meaningful clinical or commercial advantage over established agents will be a key question for European regulators and payers.

Dong-Gun Kim, chief executive of Elevar, said lirafugratinib had "demonstrated meaningful clinical activity and a differentiated safety profile consistent with its high selectivity for FGFR2 and sustained inhibitory mechanism." The company holds an exclusive worldwide commercialisation licence for lirafugratinib from Relay Therapeutics, which originated the compound.

Regulatory and competitive context

Lirafugratinib received FDA Orphan Drug Designation in 2022 and Breakthrough Therapy Designation in 2023, designations that signal the agency's recognition of early clinical promise and an unmet need in the CCA population. The EMA has a comparable orphan designation framework, and CCA's rare-disease classification in the EU may smooth parts of the MAA process, though full assessment timelines still typically run to 12 to 15 months after validation.

The second-line FGFR2-altered CCA space is competitive but not crowded. Incyte's pemigatinib and Taiho's futibatinib are approved in the US and the EU, and any new entrant will need to demonstrate either superior efficacy or a safety advantage convincing enough to shift prescribing behaviour. Elevar's selectivity narrative addresses the latter, though head-to-head data against approved agents are not yet available.

Beyond CCA, the company is running ReFocus202, a global Phase 2 basket study evaluating lirafugratinib in multiple solid tumours harbouring FGFR2 alterations, with enrolment active in the EU, UK, South Korea, and the US. A positive US approval decision later this month, if it materialises, would considerably strengthen Elevar's negotiating position with European health technology assessment bodies when the EMA process concludes.